Tag: NASDAQ: SLNO

Business

Will Soleno Therapeutics, Inc. (NASDAQ: SLNO) Sail Through From Here?

Clinical-stage biopharmaceutical company Soleno Therapeutics, Inc. (NASDAQ: SLNO) recently announced that its drug DCCR (diazoxide choline) Extended-Release tablets has received Orphan Drug Designation from U.S. Food and Drug Administration (FDA). The drug is to be used for the treatment of von Gierke disease, scientifically called Glycogen Storage Disease Type 1a […]